Výsledky vyhledávání - "Roman G, Rubio"

Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials

Autor: Nowell, Solish, Cheryl M, Burgess, Susan H, Weinkle, Glynis, Ablon, Jessica, Brown, Kristie, Kooken, Roman G, Rubio

Publikováno v: Aesthetic Surgery Journal. 43:205-214

Background DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation approved for the treatment of glabellar lines. The efficacy, safety, and extended duration of response of DAXI 40 U for glabellar lines were demonstrate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82652d2426ace6d0161775db8906aa73
https://doi.org/10.1093/asj/sjac246

Zobrazit plný text záznamu

Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study

Autor: Jeffrey S. Dover, Shannon D. Humphrey, Z. Paul Lorenc, Ava Shamban, Todd M. Gross, Roman G. Rubio, Domenico Vitarella

Publikováno v: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 49(1)

Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice.To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d29f9d850fa36138aa2e313f8d55d6
https://pubmed.ncbi.nlm.nih.gov/36533798

Zobrazit plný text záznamu

Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A

Autor: Joely Kaufman, Nowell Solish, Conor J. Gallagher, Roman G. Rubio, Todd M. Gross, Jean Carruthers

Publikováno v: Drugs

Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that maintain symptom relief between injections and reduce the frequency of re-treatment. Daxibotulin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2544e277bea6f0a24f39094931370c20
http://europepmc.org/articles/PMC8648634

Zobrazit plný text záznamu

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

Autor: Todd M. Gross, Leslie Baumann, Joel L Cohen, Jessica Brown, Roman G. Rubio, Sabrina G. Fabi, Theda C. Kontis, Conor J. Gallagher, Lawrence Green, Sunil Dhawan

Publikováno v: Dermatologic Surgery

Supplemental Digital Content is Available in the Text.
BACKGROUND DaxibotulinumtoxinA for Injection (DAXI) is botulinum toxin Type A formulated with a novel peptide excipient. Two pivotal, single-treatment, placebo-controlled trials demonstrated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed62e8d41b3ac34ead7f71a347779b8
https://doi.org/10.1097/dss.0000000000002531

Zobrazit plný text záznamu

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study

Autor: Kyle M. Coleman, Roman G. Rubio, Glynis Ablon, Conor J. Gallagher, Kavita Mariwalla, Domenico Vitarella, Susan H Weinkle, Jeremy B. Green

Publikováno v: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 47(1)

Background SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development program of an aesthetic neuromodulator in glabellar lines. Objective To evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b30d2663acf90022bd0ed0365c4033d4
https://pubmed.ncbi.nlm.nih.gov/32796331

Zobrazit plný text záznamu

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study

Autor: Allison Brashear, Roman G. Rubio, Gill Shears, Cynthia L. Comella, Chad K. Oh, Atul T. Patel, Daniel D. Truong, Marian L. Evatt, Daniel Snyder, Joseph Jankovic

Publikováno v: Movement Disorders Clinical Practice. 5:273-282

Background: Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response – and therefore less frequent dosing – than onabotulinumtoxinA. Objectives: To perform a phase 2, open-label, d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae219ad18c39486bde34dab24f6eb54b
https://doi.org/10.1002/mdc3.12613

Zobrazit plný text záznamu

Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study

Autor: Nowell Solish, Roman G. Rubio, Shannon Humphrey, Arthur Swift, Jean Carruthers, Channy Muhn, Gill Shears, Nathan Rosen, Vince Bertucci

Publikováno v: Dermatologic Surgery. 43:S262-S273

Background Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A. Published Phase 2 data show that, compared with 20U onabotulinumtoxinA, 40U daxibotulinumtoxinA is associated with a significantly greater response rate a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca3aea3898d1cc11c04e15b5f51c408
https://doi.org/10.1097/dss.0000000000001364

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání